Austrian Medical University starts a clinical trial of Argatroban Monitoring in Critically Ill Patients: Evaluation of a Novel Ecarin-based Bedside Test
The Medical University of Vienna is starting a new clinical trial of Argatroban Monitoring in Critically Ill Patients: Evaluation of a Novel Ecarin-based Bedside Test.
Argatroban is a parenteral direct Thrombininhibitor used for anticoagulation in patients suffering from heparin induced thrombocytopenia (HIT). There is increasing evidence suggesting that the activated partial thromboplastine time (aPTT), which is recommended for dosage monitoring, correlates poorly with serum argatroban concentration in critically ill patients. Therefore it may be badly suited to determine the correct dosing. Ecarin based tests have been proven to be effective in determining effects of direct thrombin inhibitors. We now plan to evaluate a novel, rotational thrombelastometric, ecarin based bedside test for its ability to measure the effect of argatroban in critically ill patients. So far an excellent correlation of a similar test could be shown in spiked plasma of healthy adults. According to the manufacturer the ECA-Test is able to detect direct thrombininhibitors. However to researcher's knowledge neither the ECA-Test nor other ecarin-based thrombelastometric tests have been studied in critically ill patients treated with argatroban. The researchers therefore seek to investigate the correlation of the ECA-Test (ClotPro®) with the serum argatroban concentration.
The clinical trial started in August 1, 2020 and will continue throughout June 1, 2022.
The population that can be enrolled into this study includes all patients at the Intensive Care Unit who receive a continuous infusion of argatroban are eligible for inclusion.
The contacts and locations are the Medical University of Vienna, General Hospital, Vienna, Austria.
The Medical University of Vienna (German: Medizinische Universität Wien) is a public university located in Vienna, Austria. It is the direct successor to the faculty of medicine at the University of Vienna, founded in 1365 by Rudolf IV, Duke of Austria. As one of the oldest medical schools in the world, it is the oldest in the German-speaking countries, and was the second medical faculty in the Holy Roman Empire, after the Charles University of Prague.
The Medical University of Vienna is the largest medical organisation in Austria, as well as one of the top-level research institutions in Europe and provides Europe's largest hospital, the Vienna General Hospital, with all of its medical staff. It consists of 31 university clinics and clinical institutes, and 12 medical-theoretical departments, which perform around 48,000 operations each year. The Vienna General Hospital has about 100,000 patients treated as inpatients and 605,000 treated as outpatients each year.
For more details: https://ichgcp.net/clinical-trials-registry/NCT04751357
